Real-World study to evaluate Fluticasone Furoate - Oxymetazoline nasal spray in Allergic Rhinitis
Not Applicable
- Conditions
- Health Condition 1: J309- Allergic rhinitis, unspecified
- Registration Number
- CTRI/2022/05/042785
- Lead Sponsor
- Zydus Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with a clinical diagnosis of allergic rhinitis or any nasal condition where-in the treating physician deems the patient suitable to receive treatment with a combination of intranasal corticosteroid and nasal decongestant will be included in the study. No further inclusion or exclusion criteria were defined beyond the information given in the package insert.
Exclusion Criteria
No further inclusion or exclusion criteria were defined beyond the information given in the package insert.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All the patients will undergo a thorough clinical evaluation as per standard / routine hospital protocol for management of allergic rhinitis at baseline and at each follow-up. Symptom scores of the last day of treatment to be compared with that of the first day of treatment for the same patient to assess for rebound congestion.Timepoint: Baseline - Day 0 <br/ ><br>First follow up - before Day 28 <br/ ><br>Second follow up - before or on Day 28
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil